Innovation | Novartis United States of America

Media Release
May 11, 2019
Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
Media Release
Jun 03, 2019
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Media Release
May 24, 2019
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
Media Release
May 24, 2019
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Media Release
Jul 16, 2019
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
Media Release
Jul 11, 2019
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
Media Release
Jun 04, 2019
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
Media Release
Sep 19, 2019
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
Media Release
Sep 02, 2019
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Media Release
Jul 22, 2019
Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
Media Release
Oct 08, 2019
Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing
Media Release
Oct 08, 2019
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept